Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vimal H Prajapati

Showing results (101-110 of 105) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 105 results.
Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
American Journal of Clinical Dermatology|September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 WeeksAlan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
Dermatology and Therapy|January 23, 2026
Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective StudyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
Clinical and Experimental Dermatology|July 29, 2025
Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicenter retrospective studyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
Dermatology and Therapy|June 3, 2025
Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort StudyTiago Torres, Jensen Yeung, Vimal H Prajapati, et al.
Pageof 11

Showing results (101-110 of 105) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 105 results.
Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
American Journal of Clinical Dermatology|September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 WeeksAlan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
Dermatology and Therapy|January 23, 2026
Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective StudyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
Clinical and Experimental Dermatology|July 29, 2025
Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicenter retrospective studyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
Dermatology and Therapy|June 3, 2025
Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort StudyTiago Torres, Jensen Yeung, Vimal H Prajapati, et al.
Pageof 11